Bellevue Life Sciences Acquisition Corp.
BLACU
NASDAQ Capital Market3.36
USD
-3.74
- -
CIK
0001840425
Return %
Stock
S&P500
1Y
-70.24
18.21
3Y
-66.93
64.38
5Y
-66.93
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kuk Hyoun Hwang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 10900 NE 4th Street Bellevue WA United States of America 98004
- IPO Date
- Feb 10, 2023
- CIK
- 0001840425
- Website
- bellevuespac.com
- Similar Companies
- Business
- Bellevue Life Sciences Acquisition Corp. (BLACU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the life sciences industry, including biotechnology, biopharmaceutical development, medical devices, and diagnostics. The company, founded in 2020 and headquartered in Bellevue, Washington, with additional offices in the Republic of Korea and Switzerland, completed its initial public offering in February 2023, raising $69 million in gross proceeds. Prior to its recent business combination, Bellevue Life Sciences Acquisition Corp. maintained no significant operations beyond pursuing such a transaction, primarily targeting opportunities in the healthcare sector on a global basis. In February 2025, Bellevue Life Sciences Acquisition Corp. completed a reverse merger with OSR Holdings Co., Ltd., a Seoul, South Korea-based global healthcare holding company operating under a hub-and-spoke model; the combined entity changed its name to OSR Holdings, Inc., with shares trading under the new ticker OSRH on Nasdaq starting February 18, 2025, while BLACU units, shares, rights, and warrants were suspended from trading. The business combination, initially announced in November 2023 and amended multiple times including in May 2024, valued the deal at approximately $240 million, with Bellevue owning at least 60% of the post-merger OSR Holdings common stock and rights to acquire additional shares. Shareholder approval occurred on February 13, 2025, following extensions of the SPAC's completion deadline, including to February 14, 2025. Through the merger, Bellevue Life Sciences Acquisition Corp. now provides access to OSR Holdings' portfolio of innovative therapies and healthcare solutions across immuno-oncology, regenerative biologics, and medical devices; core offerings include oral T-cell activation immunotherapies targeting tumor vasculature for cancer treatment via the Vaximm platform (lead asset VXM01), design-augmented biologics such as DRT-101 (a BMP super-agonist for osteoarthritis cartilage regeneration targeting 2026 IND submission), distribution of neurovascular intervention systems in Korea, and needle-free glucose monitoring devices via a July 2025 term sheet to acquire Woori IO. OSR Holdings, established in 2019, centralizes resources for its wholly-owned subsidiaries while pursuing strategic expansions, including a 2024 MOU with SillaJen for immuno-oncology synergies and evaluations of additional M&A opportunities in the U.S., Europe, and Korea. The company targets unmet medical needs in oncology, degenerative diseases, and diagnostics for patients, providers, and global markets.
Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.